Cook Medical has presented three-year data from Zilver PTX trial, which demonstrated 70.7% primary patency in the superficial femoral artery at 36 months using Paclitaxel-eluting stents. The controlled, randomized trail compares to ...
Tags: Zilver PTX trial, clinical study, clinical application, Cook Medical